Prevalence of Malignancy High in Takotsubo Syndrome Patients
WEDNESDAY, July 17, 2019 -- Overall, 16.6 percent of patients with takotsubo syndrome (TTS) have malignancy, and long-term mortality is higher in patients with malignancy, according to a study published online July 17 in the Journal of the American Heart Association.
Victoria L. Cammann, M.D., from the University Heart Center in Zurich, and colleagues enrolled TTS patients and divided the cohort into patients with and without malignancy to examine differences in clinical characteristics and assess short- and long-term malignancy. A subanalysis was performed to compare long-term mortality for a subset of TTS patients with or without malignancy and acute coronary syndrome (ACS) patients with or without malignancy.
The researchers found that 16.6 percent of 1,604 TTS patients had malignancy. Compared with patients without malignancy, patients with malignancy were older and more likely to have physical triggers but less likely to have emotional triggers. Patients with malignancy had higher long-term mortality (P < 0.001), while short-term outcomes were comparable (P = 0.17). Comparable long-term mortality was seen for TTS patients with malignancies and ACS patients with malignancies (P = 0.13). Malignancy independently predicted long-term mortality.
"The findings of the present study have unraveled a high prevalence of malignancy in TTS patients," the authors write. "Our findings suggest that specific malignancy-associated factors impact the development and outcome of TTS. Therefore, to fully understand the pathophysiology of TTS and the role of malignancy in triggering or affecting outcomes, this subset of patients deserves further investigation."
© 2020 HealthDay. All rights reserved.
Posted: July 2019
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.